The Lancet. NeurologyHumansAlzheimer DiseaseDouble-Blind MethodMalePresenilin-1
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
Pierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, Kaycee M Sink, Margarita Giraldo-Chica, Natalia Acosta-Baena, Gustavo Villegas, Alejandro Espinosa, Marisol Londoño Castaño, Claudia Muñoz, Paula Ospina, Yamile Bocanegra, Victoria Tirado, Eliana Henao, Eugenia Cardona
Published: 202610.1016/S1474-4422(25)00426-0
Abstract
BACKGROUND: To have maximal benefit, Alzheimer's disease-modifying treatments might need to be started before the onset of clinical symptoms. Mutations of the PSEN1 gene are inherited as fully penetrant, autosomal-dominant traits, which almost always…
Preview only. Read the full abstract at the source